Statistics from Altmetric.com
Although patients with systemic lupus erythematosus (SLE) are at increased risk for Streptococcus pneumoniae infection,1 2 vaccination coverage remains dramatically low in SLE,3 and efficacy of the now recommended prime-and-boost strategy using 13-valent pneumococcal conjugate vaccine (PCV13) and 23-valent pneumococcal polysaccharide vaccine (PPSV23) is not known.
Consecutive patients with SLE admitted in our daycare hospital unit were prospectively enrolled to receive PCV13 followed by PPSV23 8 weeks later. Immune protection, defined by an antigen-specific IgG concentration ≥1.3 µg/mL for at least 70% of seven pneumococcal serotypes (4, 6B, 9V, 14, 18C, 19F and 23F), was assessed at baseline, 2 and 12 months. Patients were defined as ‘long-term protected (LTP)’ when seroconversion was observed 2 months and 12 months after PCV13 shot. Patients were considered ‘short-term protected (STP)’ when seroconversion was observed 2 months but no more at 12 months after PCV13 shot. Patients were ‘not protected (NP)’ when seroconversion occurred neither 2 months nor 12 months after PCV13 shot. Laboratory tests included the analysis of blood …
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.